Verona Pharma Plc (LON:VRP) insider David Ebsworth acquired 60,000 shares of the stock in a transaction dated Thursday, August 8th. The stock was purchased at an average cost of GBX 50 ($0.65) per share, with a total value of £30,000 ($39,200.31).
Verona Pharma stock opened at GBX 46 ($0.60) on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.95 and a quick ratio of 5.60. The business has a 50 day moving average of GBX 49.63 and a 200-day moving average of GBX 55.68. The company has a market capitalization of $48.45 million and a P/E ratio of -2.46. Verona Pharma Plc has a 1 year low of GBX 42 ($0.55) and a 1 year high of GBX 127.44 ($1.67).
Verona Pharma (LON:VRP) last issued its quarterly earnings results on Tuesday, August 6th. The company reported GBX (13.65) (($0.18)) EPS for the quarter.
Verona Pharma Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis.
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.